Fa'amatalaga Fou ole tui ole Kanesa mo Tumors Malosi

Nouscom i aso nei na faʻasalalau faʻamalosia faʻamatalaga fou faʻaliliu na maua mai le faʻataʻitaʻiga Faʻaauau 1 suʻesuʻega NOUS-209. O faʻamaumauga na tuʻuina atu ananafi i le Late Breaking session i le 2022 American Association for Cancer Research (AACR) Fonotaga Faaletausaga.

NOUS-209, oloa ta'imua a Nouscom, ose tui puipui ole kanesa e fa'atatau ile 209 fa'asoa neoantigens. O loʻo suʻesuʻeina i le Vaega 1 faʻataʻitaʻiga faʻataʻitaʻiga, faʻatautaia faʻatasi ma le anti-PD-1 checkpoint inhibitor pembrolizumab, mo le togafitia o le Microsatellite Intable High (MSI-H) gastric, colorectal ma gastro-esophageal junction tumors solid.

Na tuʻuina atu muamua faʻamatalaga falemaʻi le tumau o le tuʻufaʻatasia (tuʻuina atu i le Sosaiete mo le Immunotherapy o Kanesa's (SITC) Fonotaga Faaletausaga ia Novema 2021) na faʻaalia ai faʻailoga vave o le aoga ile 12 MSI-H maʻi.

O fa'amatalaga fa'aliliuga fou na tu'uina atu i le AACR 2022 na lagolagoina atili ai nei su'esu'ega ma fa'aalia NOUS-209 e saogalemu, maualuga le immunogenic fa'atasi ai ma fa'ailoga mautinoa o le aoga. O mea taua na maua e pei ona taua i lalo:

• O le tui puipuia o tui na fa'aalia e le ex-vivo IFN-ɣ ELISpot su'ega i le 67% o tagata mama'i i le la'asaga 1 (n=3), ma le 100% (n=7) o tagata mama'i i le la'asaga 2.

• I le 3 ma'i ma'i umi PRs o lo'o maua a latou biopsies tumo a'o le'i / mae'a togafitiga, o le intratumoral TCR repertoire na fa'alauteleina ma fa'avasegaina pe a uma togafitiga ma NOUS-209. Na maitauina le si'itia o le T effector manatua ina ua mae'a togafitiga.

• I se tasi o nei ma'i e tolu, o tui neoantigen specific TCR na siaki mai pito pito i totonu ole tumo biopsy pe a uma togafitiga NOUS-209.

• O fa'ai'uga e fa'ailoa mai ai neoantigen fa'apitoa CD8 + T sela, fa'aosoina e NOUS-209, fa'alautele ma fa'a'ese'ese pe a na'o togafitiga ma NOUS-209, ma fa'aulu lelei le si'osi'omaga o le tumo e fa'atino ai le gaioiga o le tumor.

Marwan G. Fakih, MD, Medical Oncology Specialist i le City of Hope's Duarte California, ma le suʻesuʻega suʻesuʻe na fai mai: "E ui ina matou vaʻaia le alualu i luma i togafitiga mo MSI-High solid tumors i tausaga talu ai nei, o loʻo tumau pea se manaʻoga e leʻi ausia. O le mea lea e matua fa'alototeleina ai le va'ai i nei fa'aliliuga fou o le Vaega 1 fa'amatalaga o lo'o fa'aalia ai pe fa'afefea e le NOUS-209 ona fa'atupuina le fa'alauteleina o le T cell ma le TCR diversification i tagata mama'i e fa'aalia tali tumau. Ou te matua tulimatai atu i le auiliiliga atoa o le Vaega 1 iʻuga ma le faʻalauteleina o falemaʻi.

Fai mai Dr. Elisa Scarselli, Ofisa Sili o Saienitisi ma Co-Founder o Nouscom: “O faʻamaumauga, na maua mai le 12 metastatic MSI-H maʻi, o loʻo faʻamaonia ai se saini masani na matauina pe a maeʻa le tui i tagata mamaʻi e tumau le tali atu i falemaʻi. O le saini o loʻo faʻaalia e le TCR repertoire faʻalauteleina ma faʻavasegaina i lymphocytes infiltrating tumo faʻaosofia e tui ile NOUS-209, faʻatasi ai ma se faʻaopoopoga tutusa o sela T faʻatasi ma le effector memory phenotype. E le gata i lea, na mafai ona matou suʻeina tui T faʻaosoina i totonu o na faʻalauteleina pe a maeʻa togafitiga i le tuma o se tasi o nei gasegase.

"Matou te tulimatai atu e fausia a matou faʻamaoniga faʻamaonia-o-manatu faʻamaumauga e ala i le faʻaaogaina o aʻoaʻoga taua mai le faʻataʻitaʻiga faifai pea e lagolago ai le atinaʻeina o le NOUS-209 e ono avea ma tui muamua o le kanesa o le neoantigen e faʻatatau i le MSI-H tuma."